Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 231

1.
2.

Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions.

Slipicevic A, Øy GF, Askildt IC, Holth A, Hellesylt E, Flørenes VA, Davidson B.

Hum Pathol. 2009 Apr;40(4):527-37. doi: 10.1016/j.humpath.2008.10.003. Epub 2009 Jan 3.

PMID:
19121847
3.

MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells.

Davidson B, Baekelandt M, Shih IeM.

Diagn Cytopathol. 2007 Dec;35(12):756-60.

PMID:
18008338
4.

Expression of cell cycle proteins in ovarian carcinoma cells in serous effusions-biological and prognostic implications.

Davidson B, Risberg B, Berner A, Nesland JM, Tropé CG, Kristensen GB, Bryne M, Goscinski M, van de Putte G, Flørenes VA.

Gynecol Oncol. 2001 Nov;83(2):249-56.

PMID:
11606079
5.

Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival.

Brenne K, Nymoen DA, Hetland TE, Trope' CG, Davidson B.

Hum Pathol. 2012 Apr;43(4):496-505. doi: 10.1016/j.humpath.2011.05.023. Epub 2011 Aug 19.

PMID:
21855111
6.

Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma.

Rosen DG, Yang G, Deavers MT, Malpica A, Kavanagh JJ, Mills GB, Liu J.

Cancer. 2006 May 1;106(9):1925-32.

7.

Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma.

Dong HP, Kleinberg L, Silins I, Flørenes VA, Tropé CG, Risberg B, Nesland JM, Davidson B.

Cancer. 2008 Jan 1;112(1):84-93.

8.

Heparanase expression correlates with poor survival in metastatic ovarian carcinoma.

Davidson B, Shafat I, Risberg B, Ilan N, Trope' CG, Vlodavsky I, Reich R.

Gynecol Oncol. 2007 Feb;104(2):311-9. Epub 2006 Oct 9.

PMID:
17030350
9.

Expression of the peroxisome proliferator-activated receptors-alpha, -beta, and -gamma in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival.

Davidson B, Hadar R, Stavnes HT, Trope' CG, Reich R.

Hum Pathol. 2009 May;40(5):705-13. doi: 10.1016/j.humpath.2008.09.019. Epub 2009 Jan 20.

PMID:
19157507
10.

Expression and clinical role of antiapoptotic proteins of the bag, heat shock, and Bcl-2 families in effusions, primary tumors, and solid metastases in ovarian carcinoma.

Elstrand MB, Kleinberg L, Kohn EC, Tropé CG, Davidson B.

Int J Gynecol Pathol. 2009 May;28(3):211-21. doi: 10.1097/PGP.0b013e31818b0f5e.

PMID:
19620938
11.

Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.

Hanley KZ, Facik MS, Bourne PA, Yang Q, Spaulding BO, Bonfiglio TA, Xu H.

Cancer. 2008 Feb 25;114(1):49-56.

12.

Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma.

Davidson B, Alejandro E, Flørenes VA, Goderstad JM, Risberg B, Kristensen GB, Trope CG, Kohn EC.

Cancer. 2004 May 15;100(10):2139-47.

13.

AlphaV- and beta1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients.

Davidson B, Goldberg I, Reich R, Tell L, Dong HP, Trope' CG, Risberg B, Kopolovic J.

Gynecol Oncol. 2003 Aug;90(2):248-57.

PMID:
12893184
14.

The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.

Gorovetz M, Baekelandt M, Berner A, Trope' CG, Davidson B, Reich R.

Gynecol Oncol. 2006 Dec;103(3):831-40. Epub 2006 Aug 17.

PMID:
16919315
15.

Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions.

Yuan Y, Nymoen DA, Dong HP, Bjørang O, Shih IeM, Low PS, Trope' CG, Davidson B.

Hum Pathol. 2009 Oct;40(10):1453-60. doi: 10.1016/j.humpath.2009.02.013. Epub 2009 May 19.

PMID:
19454358
16.

Different clinical roles for p21-activated kinase-1 in primary and recurrent ovarian carcinoma.

Davidson B, Shih IeM, Wang TL.

Hum Pathol. 2008 Nov;39(11):1630-6. doi: 10.1016/j.humpath.2008.03.009. Epub 2008 Jul 24.

PMID:
18656238
18.

D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.

Bassarova AV, Nesland JM, Davidson B.

Am J Surg Pathol. 2006 Jul;30(7):878-82.

PMID:
16819331
19.

Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance.

Hetland TE, Hellesylt E, Flørenes VA, Tropé C, Davidson B, Kærn J.

Hum Pathol. 2011 Jul;42(7):1019-26. doi: 10.1016/j.humpath.2010.10.025. Epub 2011 Feb 11.

PMID:
21315408
20.

Expression and prognostic value of the cell-cycle regulatory proteins, Rb, p16MTS1, p21WAF1, p27KIP1, cyclin E, and cyclin D2, in ovarian cancer.

Milde-Langosch K, Hagen M, Bamberger AM, Löning T.

Int J Gynecol Pathol. 2003 Apr;22(2):168-74.

PMID:
12649672

Supplemental Content

Support Center